At 2:20 pm, the shares pared some beneficial properties, and had been buying and selling 15.2 per cent greater at Rs 2,777.15 on the BSE, whereas benchmark Sensex dropped 1 per cent to 38,225.
The corporate, which manufactures bulk medicine and chemical substances, stated on Monday its board will meet later this week to contemplate a proposal for difficulty of bonus shares.
The corporate has delivered a stellar set of numbers for the June quarter, at the same time as Covid-19 pandemic disrupted financial exercise throughout the globe.
Aarti Drug’s web revenue rose 281 per cent to Rs 85.45 crore within the quarter ended June whereas gross sales rose 34 per cent to Rs 544.67 crore within the quarter from a yr in the past.
The inventory has seen a implausible run, with its inventory leaping 373 per cent for the yr to this point, taking the beneficial properties for the final decade to three,808 per cent.